Connectome, a cognitive intelligence platform, is making waves by bringing brain measurement technology to the public. This groundbreaking development, developed in collaboration with Imperial College London, is set to revolutionize how we understand and improve brain performance. The platform's first major study, conducted with Imperial, has revealed fascinating insights into how the brain changes over time. Now, individuals can book a brain-performance scan at Connectome's clinic in Soho, London, and organizations can integrate this technology into their programs. This marks the first time that brain assessments have become commercially available, similar to how physical examinations have been accessible through wearables and blood tests.
Lucas Scherdel, Co-Founder and CEO of Connectome, emphasizes the significance of this development, stating, 'HRV and VO2 max exist for the cardiovascular system. Dexa scans measure muscle mass. Now brain measurement is possible too.' This shift in perspective highlights the brain as the largest untapped source of peak performance and longevity. By providing a clear and reliable measurement of cognitive performance, Connectome empowers individuals and organizations to take proactive steps towards optimizing brain health and performance.
The technology behind Connectome measures the brain's capacity for working memory, attention control, and cognitive flexibility against a person's own baseline. This non-invasive, wearable-grade brain imaging process takes approximately 15 minutes and can be repeated over time to track changes influenced by sleep, training load, stress, and daily life. The platform's LUCID study, conducted with Imperial College London, has shown that Connectome's biomarkers of brain activity reliably predict cognitive task responses, are stable enough to track over time, and are influenced by age, sleep, and physical activity. These findings are published as a preprint and form the basis for the recommendations and feedback provided by Connectome.
Connectome's approach is not about diagnosing pathology but rather measuring cognitive performance and complementing clinical expertise. The platform offers direct-to-consumer brain-performance scanning in London and provides a measurement layer for performance, longevity, and clinical partners. This technology is backed by research with Imperial College London and has already gained support from prominent investors, including Redstone, Octopus Ventures, Concept Ventures, The Players Fund, and strategic investors across the UK, Europe, Switzerland, and the US. With its global expansion plans and innovative approach, Connectome is poised to make a significant impact on the field of brain health and performance.
